MA33343B1 - Combinaison antitumorale comprenant le cabazitaxel et la capecitabine - Google Patents

Combinaison antitumorale comprenant le cabazitaxel et la capecitabine

Info

Publication number
MA33343B1
MA33343B1 MA34423A MA34423A MA33343B1 MA 33343 B1 MA33343 B1 MA 33343B1 MA 34423 A MA34423 A MA 34423A MA 34423 A MA34423 A MA 34423A MA 33343 B1 MA33343 B1 MA 33343B1
Authority
MA
Morocco
Prior art keywords
cabazitaxel
capecitabine
antitumor combination
antitumor
combination
Prior art date
Application number
MA34423A
Other languages
Arabic (ar)
English (en)
Inventor
Emmanuelle Magherini
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33343B1 publication Critical patent/MA33343B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION EST RELATIVE À UNE COMBINAISON PHARMACEUTIQUE ANTITUMORALE COMPRENANT LE CABAZITAXEL ET LA CAPECITABINE, CES DEUX AGENTS ANTITUMORAUX POUVANT ÊTRE SOUS FORME DE BASE, SOUS FORME D'UN SEL D'UN ACIDE PHARMACEUTIQUEMENT ACCEPTABLE OU SOUS FORME D'UN HYDRATE OU D'UN SOLVAT, DESTINÉE À TRAITER LE CANCER DU SEIN MÉTASTATIQUE CHEZ LES PATIENTES PROGRESSANT APRÈS UN TRAITEMENT ANTÉRIEUR PAR ANTHRACYCLINES ET TAXANES.
MA34423A 2009-05-06 2010-05-06 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine MA33343B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0902189A FR2945211A1 (fr) 2009-05-06 2009-05-06 Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
FR0902264A FR2945212B1 (fr) 2009-05-06 2009-05-11 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine
PCT/FR2010/050873 WO2010128258A1 (fr) 2009-05-06 2010-05-06 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine

Publications (1)

Publication Number Publication Date
MA33343B1 true MA33343B1 (fr) 2012-06-01

Family

ID=41168737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34423A MA33343B1 (fr) 2009-05-06 2010-05-06 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine

Country Status (25)

Country Link
US (1) US20120115806A1 (fr)
EP (1) EP2427187A1 (fr)
JP (1) JP2012526089A (fr)
KR (1) KR20120008069A (fr)
CN (1) CN102458392A (fr)
AU (1) AU2010244253A1 (fr)
BR (1) BRPI1011827A2 (fr)
CA (1) CA2761079A1 (fr)
CL (1) CL2011002774A1 (fr)
CO (1) CO6390103A2 (fr)
CR (1) CR20110586A (fr)
DO (1) DOP2011000336A (fr)
EA (1) EA201171360A1 (fr)
EC (1) ECSP11011435A (fr)
FR (2) FR2945211A1 (fr)
IL (1) IL216063A0 (fr)
MA (1) MA33343B1 (fr)
MX (1) MX2011011765A (fr)
NI (1) NI201100192A (fr)
NZ (1) NZ596226A (fr)
PE (1) PE20120348A1 (fr)
SG (1) SG175894A1 (fr)
TN (1) TN2011000542A1 (fr)
WO (1) WO2010128258A1 (fr)
ZA (1) ZA201108109B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
CN102068407B (zh) * 2010-12-27 2011-11-23 江苏奥赛康药业股份有限公司 一种cabazitaxel注射液及其制备方法
EP2491925A1 (fr) 2011-02-25 2012-08-29 Aventis Pharma S.A. Combinaison antitumorale comprenant du cabazitaxel et de la cisplatine
EP2620148A1 (fr) 2012-01-27 2013-07-31 Aventis Pharma S.A. Combinaison antitumorale comprenant du cabazitaxel et de la cisplatine
PL2678011T3 (pl) * 2011-02-25 2019-12-31 Aventis Pharma S.A. Kombinacja przeciwnowotworowa zawierająca kabazytaksel i cisplatynę
JP6602834B2 (ja) 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
WO2017075495A1 (fr) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Conjugués ciblés sstr, et ses particules et formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Also Published As

Publication number Publication date
IL216063A0 (en) 2012-01-31
CL2011002774A1 (es) 2012-04-20
CN102458392A (zh) 2012-05-16
US20120115806A1 (en) 2012-05-10
CA2761079A1 (fr) 2010-11-11
FR2945212A1 (fr) 2010-11-12
SG175894A1 (en) 2011-12-29
AU2010244253A1 (en) 2011-11-24
PE20120348A1 (es) 2012-04-24
CR20110586A (es) 2011-12-13
CO6390103A2 (es) 2012-02-29
ECSP11011435A (es) 2011-12-30
NZ596226A (en) 2014-01-31
BRPI1011827A2 (pt) 2016-03-22
KR20120008069A (ko) 2012-01-25
DOP2011000336A (es) 2011-12-15
ZA201108109B (en) 2013-01-30
EP2427187A1 (fr) 2012-03-14
NI201100192A (es) 2012-01-23
FR2945212B1 (fr) 2011-07-01
TN2011000542A1 (fr) 2013-05-24
WO2010128258A1 (fr) 2010-11-11
MX2011011765A (es) 2012-06-01
FR2945211A1 (fr) 2010-11-12
EA201171360A1 (ru) 2012-05-30
JP2012526089A (ja) 2012-10-25

Similar Documents

Publication Publication Date Title
MA33343B1 (fr) Combinaison antitumorale comprenant le cabazitaxel et la capecitabine
BRPI0711256A2 (pt) composições anticancerìgenas e método de tratamento de cáncer
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
HK1120441A1 (en) Drugs for treatment of ovarian cancer
EP2248519A3 (fr) Formes galéniques de film non mucoadhésifs
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
WO2005072061A3 (fr) Remedes conjugues de therapie et diagnostic du cancer
MX2009007864A (es) Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
CO5670328A2 (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
RU2010140890A (ru) Улучшенные способы противоопухолевого лечения
FI3071563T3 (fi) Syövän vastaisia aineita ja niiden valmistus
JP2015507020A5 (fr)
EP1458734A4 (fr) Derives d'isoindigo, d'indigo et d'indirubine et utilisation de ceux-ci dans le traitement de cancer
JP2012527424A5 (fr)
MX2008011473A (es) El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.
WO2005118584A3 (fr) Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
EA201270298A1 (ru) Способ лечения злокачественной опухоли
JP2008546777A5 (fr)
JP2007538066A5 (fr)
JP2008540591A5 (fr)